Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pacira Pharmaceuticals Inc (NASDAQ:PCRX)

30.85
Delayed Data
As of Dec 05
 +0.60 / +1.98%
Today’s Change
29.95
Today|||52-Week Range
80.25
-59.83%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.2B

Company Description

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. It develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company markets EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase II clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of that is in preclinical trials acute pain; and DepoTXA is currently in pre-clinical development, which is used to treat or prevent excessive blood loss during surgery by promoting hemostasis. Pacira Pharmaceuticals was founded in December 2006 and is headquartered in Parsippany, NJ.

Contact Information

Pacira Pharmaceuticals, Inc.
5 Sylvan Way
Parsippany New Jersey 07054
P:(973) 254-3560
Investor Relations:
(973) 254-3574

Employees

Shareholders

Mutual fund holders58.07%
Other institutional48.35%
Individual stakeholders12.94%

Top Executives

David M. StackChairman & Chief Executive Officer
James S. ScibettaPresident
Charles A. ReinhartChief Financial Officer
Vladimir KharitonovVice President-Research & Development
James B. JonesChief Medical Officer & Senior Vice President